Gökhan Avşar
Research Subjects
Gökhan Avşar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Musluh Hakseven
Surgical Oncology Unit, Memorial Diyarbakır Hospital, Diyarbakır, Turkey
3 shared publications - Ali Ekrem Ünal
Department of Surgical Oncology, Ankara University School of Medicine, Ankara, Turkey
2 shared publications - Rıza Deryol
Department of Surgical Oncology, Ministry of Health, Istanbul Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye
2 shared publications - Serdar Çulcu
Department of Surgical Oncology, Ankara University School of Medicine, Ankara, Turkey
2 shared publications - Ahmet Sencer Ergin
Department of General Surgery, Bağcılar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Türkiye
1 shared publication Ali Ekrem Unal
Department of surgical oncology, ankara university faculty of medicine
1 shared publication
Latest Publications
- Open Access
- 28 January 2026
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 50 (1) , 1-5
Splenectomy Does Not Increase COVID-19 Risk or Mortality in Abdominal Cancer Surgery: A Retrospective Cohort Analysis
Objective: Splenectomy is frequently performed in abdominal malignancy surgeries due to direct tumor invasion, vascular injury, or for technical reasons. Although its association with bacterial infections is well documented, the effect of splenectomy on the risk and prognosis of viral infections, particularly COVID-19, remains unclear. To evaluate the incidence of postoperative COVID-19 infection and its prognostic impact in cancer patients undergoing abdominal surgery with and without splenectomy. Methods: This retrospective, single-center study analyzed 337 patients who underwent abdominal surgery for malignancy between March 2020 and March 2022. Forty-four patients underwent splenectomy as part of their oncologic procedure. COVID-19 status, demographic characteristics, comorbidity burden (Charlson Comorbidity Index), and survival outcomes were compared between patients who underwent splenectomy and those who did not. Logistic regression and Kaplan–Meier survival analyses were performed. Results: Postoperative COVID-19 infection occurred in 18.4% of all cancer patients and in 17.7% of those who underwent splenectomy. Splenectomy was not associated with a statistically significant increase in COVID-19 risk (odds ratio (OR): 1.58; 95% CI: 0.75-3.33; P = .22). This finding remained consistent after adjustment for comorbidities (OR: 1.50; 95% CI: 0.70-3.19; P = .29). Similarly, COVID-19 infection was not a significant predictor of mortality in the splenectomy group (adjusted OR: 1.02; 95% CI: 0.22-4.59; P = .97). Kaplan–Meier survival analysis revealed comparable overall survival between patients with and without splenectomy, with no statistically significant difference observed (log-rank test, P = .54). Conclusion: Splenectomy in patients with abdominal malignancies was not found to be a risk factor for acquiring COVID-19 or for poor survival outcomes following infection. While this study suggests no detrimental effect of splenectomy on the clinical course of COVID-19 in patients with cancer, more comprehensive prospective investigations are necessary to support this conclusion. Cite this article as: Deryol R, Avşar G, Hakseven M, Çulcu S, Utkan G, Ünal AE. Splenectomy does not increase COVID-19 risk or mortality in abdominal cancer surgery: A retrospective cohort analysis. Cerrahpaşa Med J. 2026, 50, 0076, doi:10.5152/ cjm.2026.25076.
- 28 January 2026
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 50 (1) , 1-5
Open AccessSplenectomy Does Not Increase COVID-19 Risk or Mortality in Abdominal Cancer Surgery: A Retrospective Cohort Analysis
Objective: Splenectomy is frequently performed in abdominal malignancy surgeries due to direct tumor invasion, vascular injury, or for technical reasons. Although its association with bacterial infections is well documented, the effect of splenectomy on the risk and prognosis of viral infections, particularly COVID-19, remains unclear. To evaluate the incidence of postoperative COVID-19 infection and its prognostic impact in cancer patients undergoing abdominal surgery with and without splenectomy. Methods: This retrospective, single-center study analyzed 337 patients who underwent abdominal surgery for malignancy between March 2020 and March 2022. Forty-four patients underwent splenectomy as part of their oncologic procedure. COVID-19 status, demographic characteristics, comorbidity burden (Charlson Comorbidity Index), and survival outcomes were compared between patients who underwent splenectomy and those who did not. Logistic regression and Kaplan–Meier survival analyses were performed. Results: Postoperative COVID-19 infection occurred in 18.4% of all cancer patients and in 17.7% of those who underwent splenectomy. Splenectomy was not associated with a statistically significant increase in COVID-19 risk (odds ratio (OR): 1.58; 95% CI: 0.75-3.33; P = .22). This finding remained consistent after adjustment for comorbidities (OR: 1.50; 95% CI: 0.70-3.19; P = .29). Similarly, COVID-19 infection was not a significant predictor of mortality in the splenectomy group (adjusted OR: 1.02; 95% CI: 0.22-4.59; P = .97). Kaplan–Meier survival analysis revealed comparable overall survival between patients with and without splenectomy, with no statistically significant difference observed (log-rank test, P = .54). Conclusion: Splenectomy in patients with abdominal malignancies was not found to be a risk factor for acquiring COVID-19 or for poor survival outcomes following infection. While this study suggests no detrimental effect of splenectomy on the clinical course of COVID-19 in patients with cancer, more comprehensive prospective investigations are necessary to support this conclusion. Cite this article as: Deryol R, Avşar G, Hakseven M, Çulcu S, Utkan G, Ünal AE. Splenectomy does not increase COVID-19 risk or mortality in abdominal cancer surgery: A retrospective cohort analysis. Cerrahpaşa Med J. 2026, 50, 0076, doi:10.5152/ cjm.2026.25076.
- Open Access
- 3 January 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 76, 101975
Integrating prognostic nutritional index with CA19-9 improves risk stratification in pancreatic cancer
- 3 January 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 76, 101975
Open AccessIntegrating prognostic nutritional index with CA19-9 improves risk stratification in pancreatic cancer
- Open Access
- 30 September 2022
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 29 (3) , 368-377
SİLDENAFİL SİTRAT VE DEKSPANTENOLÜN YARA İYİLEŞMESİ ÜZERİNDEKİ ETKİLERİNİN KARŞILAŞTIRILMASI: DENEYSEL ÇALIŞMA
Amaç Yara iyileşmesi cerrahide yüksek morbiditeye neden olabilen ciddi bir problemdir. Yara iyileşmesini hızlandırmak, nekrozu veya iskemiyi önlemek için değişik farmakolojik ajanlar çalışılmış ve halen yaygın olarak çalışılmaya devam etmektedir. Yara iyileşmesinde klinik pratikte topikal dekspantenolün geniş kulanım alanları mevcuttur. Topikal dekspantenol hem yara bakımında hem de dermatolojik hastalıkların tedavisinde kullanılmaktadır. Bu çalışmamızda, ratlarda oluşturulan deneysel yara modelinde lokal sildenafil sitrat ve topikal dekspantenol uygulamalarının etkilerinin karşılaştırılması amaçlanmıştır. Gereç ve Yöntem Çalışmada 200–250 gram arasında değişen 30 Adet Wistar Albino dişi rat kullanıldı. Hayvanlar üç gruba ayrıldı. Deney hayvanlarının anestezisini takiben sırt orta kesimlerine 2 cm uzunluğunda tam kat kalınlıkta deri defekti oluşturuldu. Yara pansumanında tüm hayvanların yaraları steril % 0.9 NaCl solüsyonu ile yıkandıktan sonra kontrol grubu olduğu gibi bırakılırken, irigasyon sonrası 2. gruba %5’lik dekspantenol krem, 3. gruba % 10’luk sildenafil krem uygulandı. Ratlarda yara boyutları 3., 5., 7., 10., 14. ve 21. günlerde ölçülerek kaydedildi ve 21. gün tüm ratların sırt kısımlarından insizyon hattını içerecek şekilde tam kat deri çıkarılarak histolojik incelemeye alındı. Bulgular Tüm gruplara genel olarak bakıldığında günlere göre yara boyutlarındaki küçülme ve histopatolojik bulgular açısından istatiksel olarak anlamlı fark saptanmadı. Sonuç Sildenafil sitratın yara boyutunda önemli bir azalmaya yol açtığı için yara iyileşmesi için topikal bir krem olarak kullanılabileceğine inanıyoruz.
- 30 September 2022
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 29 (3) , 368-377
Open AccessSİLDENAFİL SİTRAT VE DEKSPANTENOLÜN YARA İYİLEŞMESİ ÜZERİNDEKİ ETKİLERİNİN KARŞILAŞTIRILMASI: DENEYSEL ÇALIŞMA
Amaç Yara iyileşmesi cerrahide yüksek morbiditeye neden olabilen ciddi bir problemdir. Yara iyileşmesini hızlandırmak, nekrozu veya iskemiyi önlemek için değişik farmakolojik ajanlar çalışılmış ve halen yaygın olarak çalışılmaya devam etmektedir. Yara iyileşmesinde klinik pratikte topikal dekspantenolün geniş kulanım alanları mevcuttur. Topikal dekspantenol hem yara bakımında hem de dermatolojik hastalıkların tedavisinde kullanılmaktadır. Bu çalışmamızda, ratlarda oluşturulan deneysel yara modelinde lokal sildenafil sitrat ve topikal dekspantenol uygulamalarının etkilerinin karşılaştırılması amaçlanmıştır. Gereç ve Yöntem Çalışmada 200–250 gram arasında değişen 30 Adet Wistar Albino dişi rat kullanıldı. Hayvanlar üç gruba ayrıldı. Deney hayvanlarının anestezisini takiben sırt orta kesimlerine 2 cm uzunluğunda tam kat kalınlıkta deri defekti oluşturuldu. Yara pansumanında tüm hayvanların yaraları steril % 0.9 NaCl solüsyonu ile yıkandıktan sonra kontrol grubu olduğu gibi bırakılırken, irigasyon sonrası 2. gruba %5’lik dekspantenol krem, 3. gruba % 10’luk sildenafil krem uygulandı. Ratlarda yara boyutları 3., 5., 7., 10., 14. ve 21. günlerde ölçülerek kaydedildi ve 21. gün tüm ratların sırt kısımlarından insizyon hattını içerecek şekilde tam kat deri çıkarılarak histolojik incelemeye alındı. Bulgular Tüm gruplara genel olarak bakıldığında günlere göre yara boyutlarındaki küçülme ve histopatolojik bulgular açısından istatiksel olarak anlamlı fark saptanmadı. Sonuç Sildenafil sitratın yara boyutunda önemli bir azalmaya yol açtığı için yara iyileşmesi için topikal bir krem olarak kullanılabileceğine inanıyoruz.
- Open Access
- 18 May 2022
- Published by Springer Nature in Research Square
Impact of COVID-19 Vaccination on Breast Cancer Patients; the Negative Effects of the Pandemic Have Started to Decrease.
BACKROUND The COVID-19 pandemic has caused delays in diagnosis, and treatment of breast cancer patients. We predicted that the effects of the pandemic on breast cancer patients would decrease during the post-vaccination period. METHODS The data of 131 female patients who were operated on for breast cancer between March 2019, and March 2022, were analyzed into 3 groups: the control group (CG) between March 2019–2020, the pandemic group (PG) between March 2020–2021, and the vaccine group (VG) between March 2021 - March 2022. Patient admission time (PAT), diagnosis time (DT), tumor size, TNM classification and etc data were analyzed. RESULTS Prolonged PAT times in PG compared to CG were observed to be significantly reduced in VG (p = 0.009). In both PG and VG, the DTs were prolonged significantly (p < 0.001 and p < 0.001, respectively). Tumor sizes were found to be larger in PG than in CG and VG (p = 0.003 and p = 0.001, respectively). CONCLUSION After COVID-19 vaccination; delays in diagnosis and treatment caused by the pandemic in breast cancer patients have decreased and the increase in tumor size during the pandemic period has regressed.
- 18 May 2022
- Published by Springer Nature in Research Square
Open AccessImpact of COVID-19 Vaccination on Breast Cancer Patients; the Negative Effects of the Pandemic Have Started to Decrease.
BACKROUND The COVID-19 pandemic has caused delays in diagnosis, and treatment of breast cancer patients. We predicted that the effects of the pandemic on breast cancer patients would decrease during the post-vaccination period. METHODS The data of 131 female patients who were operated on for breast cancer between March 2019, and March 2022, were analyzed into 3 groups: the control group (CG) between March 2019–2020, the pandemic group (PG) between March 2020–2021, and the vaccine group (VG) between March 2021 - March 2022. Patient admission time (PAT), diagnosis time (DT), tumor size, TNM classification and etc data were analyzed. RESULTS Prolonged PAT times in PG compared to CG were observed to be significantly reduced in VG (p = 0.009). In both PG and VG, the DTs were prolonged significantly (p < 0.001 and p < 0.001, respectively). Tumor sizes were found to be larger in PG than in CG and VG (p = 0.003 and p = 0.001, respectively). CONCLUSION After COVID-19 vaccination; delays in diagnosis and treatment caused by the pandemic in breast cancer patients have decreased and the increase in tumor size during the pandemic period has regressed.